THC Farmaceuticals Inc
OTC:CBDG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
THC Farmaceuticals Inc
EPS (Diluted)
THC Farmaceuticals Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
THC Farmaceuticals Inc
OTC:CBDG
|
EPS (Diluted)
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
UniFirst Corp
NYSE:UNF
|
EPS (Diluted)
$7
|
CAGR 3-Years
11%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
|
VSE Corp
NASDAQ:VSEC
|
EPS (Diluted)
$0
|
CAGR 3-Years
-37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-13%
|
|
|
Copart Inc
NASDAQ:CPRT
|
EPS (Diluted)
$1
|
CAGR 3-Years
13%
|
CAGR 5-Years
17%
|
CAGR 10-Years
22%
|
|
|
Aurora Innovation Inc
NASDAQ:AUR
|
EPS (Diluted)
$0
|
CAGR 3-Years
34%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Cintas Corp
NASDAQ:CTAS
|
EPS (Diluted)
$4
|
CAGR 3-Years
15%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
THC Farmaceuticals Inc
Glance View
THC Farmaceuticals, Inc. engages in the research and development of cannabis pharmaceutical products. The company is headquartered in Scottsdale, Arizona. The company went IPO on 2012-08-22. The firm through its subsidiary CBDual Biotechnology Corp., a pharmaceutical start-up company focuses on developing products based on cannabidiol (CBD) and/or Tetrahydrocannabinol (THC). The firm is engaged cannabis formulations, edibles, and delivery systems of cannabis. The company manufactures and markets cannabis extract products made from cannabis. The firm's facility is located in Southern California. The company provides access for patients to participate in clinical trials of new medical cannabis medications, therapies, and products. The firm is focusing on the research of psilocybin for the purpose of conducting clinical trials involving the combination of genetic testing and micro-dosing of psilocybin formulations.
See Also
What is THC Farmaceuticals Inc's EPS (Diluted)?
EPS (Diluted)
0
USD
Based on the financial report for Sep 30, 2022, THC Farmaceuticals Inc's EPS (Diluted) amounts to 0 USD.
